4investors | Börsen-News | Adhoc- und Unternehmensnews | Biofrontera

DGAP-News: Biofrontera AG: Annual General Meeting of Biofrontera AG: Biofrontera Management Board approved by large majority

Bild und Copyright: Michael Barck / www.4investors.de.

Bild und Copyright: Michael Barck / www.4investors.de.

11.07.2019, 11:20:02 (www.4investors.de - in Kooperation mit DGAP - EQS Group):




DGAP-News: Biofrontera AG / Key word(s): AGM/EGM

Biofrontera AG: Annual General Meeting of Biofrontera AG: Biofrontera Management Board approved by large majority
11.07.2019 / 11:20


The issuer is solely responsible for the content of this announcement.
Annual General Meeting of Biofrontera AG: Biofrontera Management Board approved by large majorityLeverkusen, Germany, July 11, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the results of the Annual General Meeting held on 10 July 2019. The shareholders present represented 75.88% of the registered share capital.

The shareholders approved the agenda items proposed by the Management Board and Supervisory Board (published in the Federal Gazette on June 3, 2019) with a large majority. All supplementary motions and countermotions submitted by the Deutsche Balaton Group were rejected by the Annual General Meeting with a clear majority. Prof. Dr. Franca Ruhwedel was newly appointed to the Supervisory Board. In the future, she will support Biofrontera AG with her extensive financial expertise, in particular in the Audit Committee. No vote was required on agenda item 1.

"The overwhelming shareholder presence at yesterday's Annual General Meeting shows the strong interest and commitment of our shareholders. The rejection of all supplementary motions and countermotions shows that our shareholders stand united behind the Management Board and Supervisory Board. We greatly appreciate the support and would like to express our sincere thanks," said CEO Prof. Dr. Hermann Lübbert. "We see ourselves confirmed on our strategic course and will continue to work on the success of the Company with the outstanding know-how and tireless commitment of our employees".

Reinhard Eyring, member of the Supervisory Board and chairman of yesterday's meeting, added: "On behalf of the Supervisory Board, I would like to welcome Prof. Dr. Ruhwedel as a new member of the Supervisory Board of Biofrontera. My colleagues and I look forward to working together".

Further information on the Annual General Meeting including the detailed voting results and the Executive Board presentation can be found at: https://www.biofrontera.com/en/annual-general-meeting.html

-End-

For enquiries, please contact:
Biofrontera AG
Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen

+44 (0) 207 229 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592
 

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets AKTIPAK(R), a prescription medication for the treatment of acne, and Xepi(TM) for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

Forward Looking Statements:

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

 












11.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
Biofrontera AG

Hemmelrather Weg 201

51377 Leverkusen


Germany
Phone:
+49 (0)214 87632 0
Fax:
+49 (0)214 87632 90
E-mail:
ir@biofrontera.com
Internet:
www.biofrontera.com
ISIN:
DE0006046113, NASDAQ: BFRA
WKN:
604611
Listed:
Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID:
839879

 
End of News
DGAP News Service




839879  11.07.2019 



(Werbung)

Exklusiv-Berichte und Interviews aus der 4investors Redaktion:

VERIANOS-Vorstand Tobias Bodamer spricht im Interview mit der 4investors-Redaktion über Immobilien in Spanien und Deutschland, das Geschäftsmodell, Fonds und eine mögliche Anleihe-Emission.VERIANOS Real Estate: Immobilien mit überdurchschnittlich attraktiven Renditen

4investors-Newsletter

Exklusive Interviews und Analysen für Sie aus der 4investors-Redaktion!

Der Newsletter ist kostenlos. Sie können den Newsletter jederzeit wieder abbestellen. Wir speichern Ihre Mailadresse ausschließlich zum Versand des Newsletters und geben diese nicht weiter! Bitte beachten Sie unsere Datenschutzerklärung.

Weitere DGAP-News von Biofrontera

19.02.2020 - DGAP-News: Biofrontera AG: Biofrontera veröffentlicht Neues aus der klinischen Entwicklung
03.02.2020 - DGAP-News: Biofrontera AG: Europäische Zulassungsbehörde empfiehlt die Zulassungserweiterung von Ameluz(R) zur Behandlung von aktinischen Keratosen auf Extremitäten sowie Rumpf/ Nacken
31.01.2020 - DGAP-News: Biofrontera AG: Organisatorische Neustrukturierung der Biofrontera und Rücktritt des Vertriebsvorstands Christoph Dünwald
14.01.2020 - DGAP-News: Biofrontera AG: Biofrontera veröffentlicht 1-Jahres Follow-up-Ergebnisse für ihre Phase III-Studie zur photodynamischen Therapie von aktinischer Keratose an den Extremitäten und am Rumpf/Hals
10.01.2020 - DGAP-Adhoc: Biofrontera AG: Biofrontera gibt vorläufige Umsatzzahlen für das Gesamtjahr 2019 bekannt, Rekordumsatz im 4. Quartal

4investors-News zu Biofrontera

10.02.2020 - Biofrontera: Sieht nicht gut aus bei der Aktie…
06.02.2020 - Biofrontera: Neues Kursziel für die Aktie
03.02.2020 - Biofrontera: EU-Zulassung für Ameluz soll erweitert werden
01.02.2020 - Biofrontera: Vertriebsvorstand geht
14.01.2020 - Biofrontera meldet Follow-up-Ergebnisse für klinische Ameluz-Studie
10.01.2020 - Biofrontera: Hier ist richtig was los…
06.01.2020 - Biofrontera: News aus dem US-Geschäft
13.12.2019 - Biofrontera: Neuer Manager für das US-Geschäft
05.12.2019 - Biofrontera: Analyst senkt Kursziel für die Aktie
02.12.2019 - Biofrontera Aktie: Nach der Kurshalbierung nun die Erholungsrallye?
21.11.2019 - Biofrontera Aktie: Comeback oder nur eine Zwischenerholung?
19.11.2019 - Biofrontera verpasst Ziele - rote Zahlen für 2019 prognostiziert
17.10.2019 - Biofrontera Aktie: Neues Kursziel gesetzt
10.10.2019 - Biofrontera: „Wachstum in Deutschland weiterhin sehr dynamisch”
10.10.2019 - Biofrontera Aktie: Zwei ganz wichtige Unterstützungen!
27.09.2019 - Biofrontera-Aktie verzeichnet „Comeback-Stimmung”
17.09.2019 - Biofrontera will Erweiterung der EU-Zulassung für Ameluz
29.08.2019 - Biofrontera: Erwartungen werden angepasst
27.08.2019 - Biofrontera: Break-even soll im vierten Quartal erreicht werden
05.08.2019 - Biofrontera muss sich in USA vorerst auf Ameluz- und Xepi-Vertrieb konzentrieren